Abbott Launches Next-Generation Navitor Vision Transcatheter Aortic Valve System in the U.S.

Mar 15, 2024 00:01 CST Updated 00:01

Abbott

Diagnostic and pharmaceutical product manufacturers

Source of the article:Heart NotCome;Editor: Sophia

Reprint requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.

Heart Future

On March 14, 2024, Abbott (NYSE: ABT) announced its launch in the United States.The Latest Generation Navitor Vision Heart Valve System, New SystemStable and precise delivery, low paravalvular leakage (PVL), with clear and easy-to-understand markers.Help identify.

Vice President of Abbott for Transcatheter Aortic Valve Implantation (TAVI)Chris Waddel (Waddel)Expressed on social platforms:"Hope Abbott will continue to shine in the TAVI field,The advantages of the latest Navitor Vision TAVI system are more pronounced.。”

# New Navitor Vision System

Navitor has NaviSealUnique Fabric Sleeve Design, canReduce or eliminate blood regurgitation around the valve, known as paravalvular leak (PVL).。

Navitor isThe only self-expanding TAVI system with a valve within the native valve。This design helps improve access to the coronary arteries, facilitating future surgeries for treating coronary artery disease.

The design of the Navitor system alsoBeneficial toBloodFluid flows through the valve. This system adopts a slim design to accommodate different patients.Anatomical structure.

The 30-day data analysis published on the Abbott website also shows,The Superior Safety and Effectiveness of the Navitor TAVI System in Transcatheter Aortic Valve Implantation (TAVI) Procedures。

In this Navitor Vision system, Abbott is equipped with"The largest valve," "the most compact delivery system," and highly visible markers。These markers identify depths of 3mm-4.5mm, optimizing implant and patient outcomes.

# Advancing in the Cardiovascular Field

Abbott initially entered the U.S. TAVR and TAVI markets in 2021.

In 2021,Abbott'sPortico™ with FlexNav™Transcatheter Aortic Valve Replacement (TAVR) System Receives FDA Approval.
In January 2023, the company received FDA approval for the Navitor system.It is designed by Navitor as the only self-expanding TAVI system with leaflets native to the valve. This design helps improve access to the coronary arteries to facilitate future surgeries for treating coronary artery disease.

In February 2023, Abbott also announced plansAcquisition of Cardiovascular Systems (Nasdaq: CSII) Enhances Its Cardiovascular Product Line。

About Abbott

Abbott (NYSE: ABT) is a global healthcare company founded in 1888, with its headquarters in Chicago, USA. After a century of development, the company has now become a Fortune 500 enterprise with diversified pharmaceutical and nutritional products.

AbbottBusiness spans across more than 160 countries and regions worldwide, with nearly 110,000 employees., with products covering the fields of nutritional products, pharmaceuticals, medical devices, diagnostic instruments, and reagents.

2023Abbott Q4Year-on-year revenueIncrease by 1.5%, reaching$10.24 billionAmong them,Medical Device Segment Revenue was $4.44 billion, a year-over-year increase of 17.5%.。

# Global Leading Cardiovascular Device Company

Medtronic｜J&J MedTech|Boston ScientificBoston Scientific|

Edwards Lifesciences | Abbott Abbott｜

# Cardiovascular Device Companies Listed in China

# Innovative Devices Approved in China in 2023

China Cardiovascular Innovation Device List [2023 Year in Review]

#2023 Medical Devices Entering China's Innovation Pathway

XinQing Medical (NyokAssist Interventional Ventricular Assist System)

Beixins Life (Cardiac Pulse Field Ablation)

Hanling Medical (Transcatheter Aortic Valve)

# Other Unlisted/Start-up Cardiovascular Companies

Editor-in-Chief | Zhao Qing Reviewed by | Yi He